Sapho Bio Acquisition | Healthcare Deal in CA

Sapho Bio has completed the acquisition of Sapho Bio, a diagnostics imaging business in California, for $5M. Sapho Bio develops rapid sterility testing for precision medicine, using an RNA-based detection workflow built on standard qPCR to identify viable bacteria and fungi. The company’s service and sterility testing kit are designed to replace the traditional 14-day USP sterility test with results in about 20 hours for faster pharmaceutical release decisions in San Carlos, CA. The other acquisition is a healthcare M&A CA deal supporting commercialization readiness through USP<1223> validation across hundreds of samples, including accuracy, precision, and limit of detection. Founded in 2024 and backed by strategic partner Mochi Health, the platform targets QC lab adoption and rapid microbiology release, with advisors including Professor Jason Kahn and Richard Sportsman.